{"product_id":"vip-10mg-vial","title":"VIP 10mg vial","description":"\u003cp data-end=\"509\" data-start=\"85\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                               \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"509\" data-start=\"85\"\u003e\u003cstrong data-end=\"124\" data-start=\"85\"\u003eVasoactive intestinal peptide (VIP)\u003c\/strong\u003e is a naturally occurring \u003cstrong data-end=\"180\" data-start=\"150\"\u003e28–amino-acid neuropeptide\u003c\/strong\u003e widely expressed in the \u003cstrong data-end=\"277\" data-start=\"205\"\u003eenteric nervous system, peripheral nerves, immune cells, and the CNS\u003c\/strong\u003e. It functions as a \u003cstrong data-end=\"361\" data-start=\"297\"\u003eneurotransmitter\/neuromodulator and immunoregulatory peptide\u003c\/strong\u003e, with prominent roles in \u003cstrong data-end=\"471\" data-start=\"387\"\u003evasodilation, smooth-muscle relaxation, epithelial secretion, and immune “tone.”\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"709\" data-start=\"511\"\u003eClinically, most “VIP therapy” discussions involve \u003cstrong data-end=\"575\" data-start=\"562\"\u003eaviptadil\u003c\/strong\u003e, a \u003cstrong data-end=\"596\" data-start=\"579\"\u003esynthetic VIP\u003c\/strong\u003e (often formulated for IV or inhaled delivery in investigational programs). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"714\" data-start=\"711\"\u003e\n\u003ch3 data-end=\"766\" data-start=\"716\"\u003e2) Molecular pharmacology and receptor biology\u003c\/h3\u003e\n\u003ch4 data-end=\"786\" data-start=\"768\"\u003e2.1 Receptors\u003c\/h4\u003e\n\u003cp data-end=\"835\" data-start=\"787\"\u003eVIP signals primarily through \u003cstrong data-end=\"834\" data-start=\"817\"\u003eclass B GPCRs\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"875\" data-start=\"836\"\u003e\n\u003cli data-end=\"855\" data-start=\"836\"\u003e\n\u003cp data-end=\"855\" data-start=\"838\"\u003e\u003cstrong data-end=\"855\" data-start=\"838\"\u003eVPAC1 (VIPR1)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"875\" data-start=\"856\"\u003e\n\u003cp data-end=\"875\" data-start=\"858\"\u003e\u003cstrong data-end=\"875\" data-start=\"858\"\u003eVPAC2 (VIPR2)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1028\" data-start=\"877\"\u003eBoth are activated by VIP (and also by PACAP), whereas \u003cstrong data-end=\"940\" data-start=\"932\"\u003ePAC1\u003c\/strong\u003e is PACAP-preferring and has low affinity for VIP. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4 data-end=\"1058\" data-start=\"1030\"\u003e2.2 Canonical signaling\u003c\/h4\u003e\n\u003cp data-end=\"1383\" data-start=\"1059\"\u003eVPAC receptor activation typically couples to \u003cstrong data-end=\"1148\" data-start=\"1105\"\u003eGs → adenylyl cyclase → cAMP → PKA\/CREB\u003c\/strong\u003e. Depending on cell type and receptor context, VIP signaling can also engage additional pathways (e.g., β-arrestin-linked regulation, other G-protein coupling, receptor oligomerization\/regulation). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4 data-end=\"1447\" data-start=\"1385\"\u003e2.3 Systems-level physiology (why VIP “hits many organs”)\u003c\/h4\u003e\n\u003cp data-end=\"1505\" data-start=\"1448\"\u003eVIP’s pleiotropy comes from receptor distribution across:\u003c\/p\u003e\n\u003cul data-end=\"1783\" data-start=\"1506\"\u003e\n\u003cli data-end=\"1563\" data-start=\"1506\"\u003e\n\u003cp data-end=\"1563\" data-start=\"1508\"\u003e\u003cstrong data-end=\"1548\" data-start=\"1508\"\u003eVascular smooth muscle \u0026amp; endothelium\u003c\/strong\u003e → vasodilation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1613\" data-start=\"1564\"\u003e\n\u003cp data-end=\"1613\" data-start=\"1566\"\u003e\u003cstrong data-end=\"1577\" data-start=\"1566\"\u003eAirways\u003c\/strong\u003e → bronchodilation, immunomodulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1676\" data-start=\"1614\"\u003e\n\u003cp data-end=\"1676\" data-start=\"1616\"\u003e\u003cstrong data-end=\"1628\" data-start=\"1616\"\u003eGI tract\u003c\/strong\u003e → secretion, motility, smooth muscle relaxation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1783\" data-start=\"1677\"\u003e\n\u003cp data-end=\"1783\" data-start=\"1679\"\u003e\u003cstrong data-end=\"1695\" data-start=\"1679\"\u003eImmune cells\u003c\/strong\u003e → cytokine modulation and inflammatory regulation \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"1788\" data-start=\"1785\"\u003e\n\u003ch3 data-end=\"1846\" data-start=\"1790\"\u003e3) Immunology and inflammation: what VIP tends to do\u003c\/h3\u003e\n\u003cp data-end=\"2163\" data-start=\"1847\"\u003eVIP is often characterized as \u003cstrong data-end=\"1918\" data-start=\"1877\"\u003eanti-inflammatory \/ immune-modulating\u003c\/strong\u003e in many contexts, including suppression of pro-inflammatory cytokine programs and shaping immune cell responses. This is a major reason it has been explored in inflammatory disease and lung injury settings. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"2168\" data-start=\"2165\"\u003e\n\u003ch3 data-end=\"2237\" data-start=\"2170\"\u003e4) Pharmacokinetics and delivery constraints (a key limitation)\u003c\/h3\u003e\n\u003cp data-end=\"2426\" data-start=\"2238\"\u003eA central translational problem is that \u003cstrong data-end=\"2327\" data-start=\"2278\"\u003enative VIP is degraded very rapidly in plasma\u003c\/strong\u003e, with a reported half-life on the order of \u003cstrong data-end=\"2387\" data-start=\"2371\"\u003e~1–2 minutes\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"2472\" data-start=\"2428\"\u003eThis is why development work has emphasized:\u003c\/p\u003e\n\u003cul data-end=\"2686\" data-start=\"2473\"\u003e\n\u003cli data-end=\"2539\" data-start=\"2473\"\u003e\n\u003cp data-end=\"2539\" data-start=\"2475\"\u003e\u003cstrong data-end=\"2493\" data-start=\"2475\"\u003elocal delivery\u003c\/strong\u003e (e.g., inhalation for lung-targeted effects),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2569\" data-start=\"2540\"\u003e\n\u003cp data-end=\"2569\" data-start=\"2542\"\u003e\u003cstrong data-end=\"2564\" data-start=\"2542\"\u003estabilized analogs\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2686\" data-start=\"2570\"\u003e\n\u003cp data-end=\"2686\" data-start=\"2572\"\u003e\u003cstrong data-end=\"2595\" data-start=\"2572\"\u003eformulation systems\u003c\/strong\u003e to reduce systemic side effects and extend activity. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"2691\" data-start=\"2688\"\u003e\n\u003ch3 data-end=\"2757\" data-start=\"2693\"\u003e5) Clinical and translational evidence (what’s most studied)\u003c\/h3\u003e\n\u003ch4 data-end=\"2843\" data-start=\"2759\"\u003e5.1 Pulmonary vascular disease \/ pulmonary hypertension (inhaled VIP\/aviptadil)\u003c\/h4\u003e\n\u003cp data-end=\"3200\" data-start=\"2844\"\u003eInhaled aviptadil has been studied as a \u003cstrong data-end=\"2909\" data-start=\"2884\"\u003epulmonary vasodilator\u003c\/strong\u003e with the aim of producing \u003cstrong data-end=\"2974\" data-start=\"2936\"\u003elung-selective hemodynamic effects\u003c\/strong\u003e while limiting systemic hypotension; published clinical work in pulmonary hypertension reported \u003cstrong data-end=\"3097\" data-start=\"3071\"\u003emodest and short-lived\u003c\/strong\u003e pulmonary vasodilation without major side effects in that study. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4 data-end=\"3249\" data-start=\"3202\"\u003e5.2 ARDS and COVID-19 (aviptadil programs)\u003c\/h4\u003e\n\u003cp data-end=\"3742\" data-start=\"3250\"\u003eVIP biology (alveolar\/immune modulation + vascular effects) motivated multiple ARDS\/COVID programs, including \u003cstrong data-end=\"3388\" data-start=\"3360\"\u003einhaled aviptadil trials\u003c\/strong\u003e. Clinical trial registrations remain the best canonical source for what was tested and the endpoints. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr data-end=\"3531\" data-start=\"3528\"\u003eA 2025 peer-reviewed report in hospitalized COVID-19 pneumonia described inhaled aviptadil as \u003cstrong data-end=\"3643\" data-start=\"3625\"\u003ewell tolerated\u003c\/strong\u003e and associated with faster recovery in that study setting. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cblockquote data-end=\"3958\" data-start=\"3744\"\u003e\n\u003cp data-end=\"3958\" data-start=\"3746\"\u003eRegulatory nuance: “Orphan Drug Designation” has been granted for certain aviptadil development programs (e.g., ARDS\/sarcoidosis), but that is \u003cstrong data-end=\"3917\" data-start=\"3889\"\u003enot the same as approval\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003ch4 data-end=\"4003\" data-start=\"3960\"\u003e5.3 Migraine\/vascular headache biology\u003c\/h4\u003e\n\u003cp data-end=\"4225\" data-start=\"4004\"\u003eVIP is vasoactive in cranial circulation and has been used experimentally to probe neurovascular mechanisms (e.g., infusion paradigms assessing vasodilation and headache responses). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"4230\" data-start=\"4227\"\u003e\n\u003ch3 data-end=\"4286\" data-start=\"4232\"\u003e6) Safety and tolerability (mechanism-predictable)\u003c\/h3\u003e\n\u003cp data-end=\"4437\" data-start=\"4287\"\u003eBecause VIP is a strong vasodilator\/secretagogue, systemic exposure is commonly associated with \u003cstrong data-end=\"4412\" data-start=\"4383\"\u003edose- and route-dependent\u003c\/strong\u003e adverse effects such as:\u003c\/p\u003e\n\u003cul data-end=\"4641\" data-start=\"4438\"\u003e\n\u003cli data-end=\"4522\" data-start=\"4438\"\u003e\n\u003cp data-end=\"4522\" data-start=\"4440\"\u003e\u003cstrong data-end=\"4468\" data-start=\"4440\"\u003edecreased blood pressure\u003c\/strong\u003e, \u003cstrong data-end=\"4498\" data-start=\"4470\"\u003etachycardia\/palpitations\u003c\/strong\u003e, \u003cstrong data-end=\"4522\" data-start=\"4500\"\u003ecutaneous flushing\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4641\" data-start=\"4523\"\u003e\n\u003cp data-end=\"4641\" data-start=\"4525\"\u003e\u003cstrong data-end=\"4539\" data-start=\"4525\"\u003eGI effects\u003c\/strong\u003e, including diarrhea\/watery-diarrhea syndrome in some contexts \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4795\" data-start=\"4643\"\u003eThese predictable effects are a major reason inhaled delivery and lung-targeted formulations have been explored. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"4800\" data-start=\"4797\"\u003e\n\u003ch3 data-end=\"4843\" data-start=\"4802\"\u003e7) Current status (practical summary)\u003c\/h3\u003e\n\u003cul data-end=\"5369\" data-start=\"4844\"\u003e\n\u003cli data-end=\"5002\" data-start=\"4844\"\u003e\n\u003cp data-end=\"5002\" data-start=\"4846\"\u003e\u003cstrong data-end=\"4878\" data-start=\"4846\"\u003eVIP is an endogenous peptide\u003c\/strong\u003e with strong mechanistic rationale across pulmonary, vascular, and immune biology. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5158\" data-start=\"5003\"\u003e\n\u003cp data-end=\"5158\" data-start=\"5005\"\u003e\u003cstrong data-end=\"5047\" data-start=\"5005\"\u003eNative VIP is hard to use systemically\u003c\/strong\u003e due to \u003cstrong data-end=\"5081\" data-start=\"5055\"\u003every rapid degradation\u003c\/strong\u003e and \u003cstrong data-end=\"5115\" data-start=\"5086\"\u003evasodilatory side effects\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5369\" data-start=\"5159\"\u003e\n\u003cp data-end=\"5369\" data-start=\"5161\"\u003eMost real-world “VIP as a drug” efforts center on \u003cstrong data-end=\"5224\" data-start=\"5211\"\u003eaviptadil\u003c\/strong\u003e and \u003cstrong data-end=\"5252\" data-start=\"5229\"\u003edelivery strategies\u003c\/strong\u003e (especially inhaled) in pulmonary indications and ARDS\/COVID-related trials. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5374\" data-start=\"5371\"\u003e\n\u003ch3 data-end=\"5412\" data-start=\"5376\"\u003eSelected references (high-yield)\u003c\/h3\u003e\n\u003cul data-end=\"5935\" data-start=\"5413\"\u003e\n\u003cli data-end=\"5493\" data-start=\"5413\"\u003e\n\u003cp data-end=\"5493\" data-start=\"5415\"\u003eVPAC receptor biology and signaling: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5602\" data-start=\"5494\"\u003e\n\u003cp data-end=\"5602\" data-start=\"5496\"\u003ePhysiology overview (VIP\/PACAP receptors and GI\/vascular roles): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5742\" data-start=\"5603\"\u003e\n\u003cp data-end=\"5742\" data-start=\"5605\"\u003eImmunology + PK\/side-effect constraints (half-life; hypotension\/tachycardia\/flushing\/diarrhea): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5841\" data-start=\"5743\"\u003e\n\u003cp data-end=\"5841\" data-start=\"5745\"\u003ePulmonary delivery rationale + lung-selective effects: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5935\" data-start=\"5842\"\u003e\n\u003cp data-end=\"5935\" data-start=\"5844\"\u003eARDS\/COVID trial registry and 2025 inhaled study\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684841845074,"sku":null,"price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/VIP10mg.png?v=1770834799","url":"https:\/\/sciencepeptideslab.com\/products\/vip-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}